Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Common Equity: 2020-2024

Historic Common Equity for Foghorn Therapeutics (FHTX) over the last 5 years, with Dec 2024 value amounting to -$45.5 million.

  • Foghorn Therapeutics' Common Equity fell 216.96% to -$89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year decrease of 216.96%. This contributed to the annual value of -$45.5 million for FY2024, which is 41.02% up from last year.
  • As of FY2024, Foghorn Therapeutics' Common Equity stood at -$45.5 million, which was up 41.02% from -$77.2 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Common Equity registered a high of $146.2 million during FY2020, and its lowest value of -$77.2 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was -$45.5 million (2024), whereas its average is -$40.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 69,019.64% in 2023, then spiked by 41.02% in 2024.
  • Foghorn Therapeutics' Common Equity (Yearly) stood at $146.2 million in 2020, then tumbled by 33.73% to $96.9 million in 2021, then crashed by 99.88% to $112,000 in 2022, then slumped by 69,019.64% to -$77.2 million in 2023, then surged by 41.02% to -$45.5 million in 2024.